<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font3" size="7" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font4" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font5" size="9" family="SymbolMT" color="#000000"/>
	<fontspec id="font6" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="9" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font9" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font10" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
<text top="42" left="56" width="181" height="7" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Breast Cancer Research Vol 8 No 6    Harris et al.<b>Breast Cancer Research</b></text>
<text top="758" left="56" width="45" height="7" font="font1" id="p1_t2" reading_order_no="110" segment_no="16" tag_type="text">Page 4 of 12</text>
<text top="768" left="56" width="120" height="6" font="font3" id="p1_t3" reading_order_no="111" segment_no="17" tag_type="text">(page number not for citation purposes)<i>et al.</i></text>
<text top="85" left="56" width="240" height="9" font="font4" id="p1_t4" reading_order_no="1" segment_no="1" tag_type="text">Cohen's kappa statistic was used to measure the level of</text>
<text top="97" left="56" width="240" height="9" font="font4" id="p1_t5" reading_order_no="2" segment_no="1" tag_type="text">agreement between HER2 assay methods. We used a test of<i>(page number not for citation purposes)</i></text>
<text top="109" left="56" width="241" height="9" font="font4" id="p1_t6" reading_order_no="3" segment_no="1" tag_type="text">proportions to compare patient characteristics that were</text>
<text top="120" left="56" width="240" height="9" font="font4" id="p1_t7" reading_order_no="4" segment_no="1" tag_type="text">dichotomous. For patient characteristics collected as continu-</text>
<text top="132" left="56" width="240" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="1" tag_type="text">ous variables, we compared median values, using the Wil-</text>
<text top="144" left="56" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="1" tag_type="text">coxon rank-sum test. Response rates were compared on the</text>
<text top="156" left="56" width="240" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="1" tag_type="text">basis of categorization of clinical variables and HER2 and p53</text>
<text top="167" left="56" width="240" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="1" tag_type="text">status, with the use of a test of proportions. Time to treatment</text>
<text top="179" left="56" width="240" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="1" tag_type="text">failure (TTF) was measured as the time from study entry to the</text>
<text top="191" left="56" width="240" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="1" tag_type="text">first locoregional recurrence, first distant metastasis, or death</text>
<text top="203" left="56" width="240" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="1" tag_type="text">due to any cause; data were censored for patients without</text>
<text top="214" left="56" width="240" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="1" tag_type="text">events at the last follow-up date. OS was measured as the</text>
<text top="226" left="56" width="240" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="1" tag_type="text">time from study entry to death, with data censored at the last</text>
<text top="238" left="56" width="241" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="1" tag_type="text">follow up. Time to event and Kaplan-Meier curves were com-</text>
<text top="250" left="56" width="240" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="1" tag_type="text">pared using the log-rank test. Hazard ratios and their 95%</text>
<text top="261" left="56" width="240" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="1" tag_type="text">confidence intervals (CIs) were calculated for multivariate Cox</text>
<text top="273" left="56" width="240" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="1" tag_type="text">proportional hazards modeling. The significance of variables in</text>
<text top="282" left="56" width="240" height="12" font="font4" id="p1_t21" reading_order_no="18" segment_no="1" tag_type="text">multivariate Cox models was determined using the Ï‡ 2 test. All</text>
<text top="297" left="56" width="123" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="1" tag_type="text">statistical tests were two sided.</text>
<text top="320" left="56" width="39" height="10" font="font7" id="p1_t23" reading_order_no="20" segment_no="9" tag_type="title">Results</text>
<text top="332" left="56" width="229" height="8" font="font8" id="p1_t24" reading_order_no="21" segment_no="10" tag_type="title">Baseline and follow-up characteristics of the patients</text>
<text top="344" left="56" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="11" tag_type="text">Paraffin-embedded tissue blocks were available for 201 of the</text>
<text top="355" left="56" width="240" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="11" tag_type="text">474 patients enrolled in CALGB 9342. Blocks from 175</text>
<text top="367" left="56" width="241" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="11" tag_type="text">patients passed quality control. A total of 165 patients with at</text>
<text top="379" left="56" width="240" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="11" tag_type="text">least one biomarker measurement are included in this com-<b>Results</b></text>
<text top="391" left="56" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="11" tag_type="text">panion study. The median follow-up time was 8.3 years among<b>Baseline and follow-up characteristics of the patients</b></text>
<text top="402" left="56" width="240" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="11" tag_type="text">patients with at least one biomarker measurement and 8.5</text>
<text top="414" left="56" width="240" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="11" tag_type="text">years for the remaining study population (Table 1). The only</text>
<text top="426" left="56" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="11" tag_type="text">significant difference between the two groups was the shorter</text>
<text top="438" left="56" width="240" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="11" tag_type="text">median disease-free interval among patients with biomarker</text>
<text top="449" left="56" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="11" tag_type="text">measurements (19 versus 31 months; P = 0.0003). Because</text>
<text top="461" left="56" width="240" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="11" tag_type="text">blocks are often discarded after 10 years, patients with availa-</text>
<text top="85" left="315" width="240" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="2" tag_type="text">ble blocks would, by definition, have a shorter interval between<a href=""> 1).</a> The only</text>
<text top="97" left="315" width="101" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="2" tag_type="text">diagnosis and metastasis.</text>
<text top="120" left="315" width="175" height="8" font="font8" id="p1_t38" reading_order_no="35" segment_no="3" tag_type="title">Hormone receptor, HER2, and p53 status</text>
<text top="132" left="315" width="240" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="4" tag_type="text">Information on hormone receptor status was available for 148</text>
<text top="144" left="315" width="240" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="4" tag_type="text">of the 201 patients from whom tissue blocks were collected.<i>P </i></text>
<text top="156" left="315" width="240" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="4" tag_type="text">Of these 148 patients, 74 (50%) had tumors that were</text>
<text top="167" left="315" width="164" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="4" tag_type="text">reported to be hormone receptor positive.</text>
<text top="191" left="315" width="240" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="5" tag_type="text">The CB11 assay of HER2 was informative in 162 cases, the</text>
<text top="203" left="315" width="240" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="5" tag_type="text">HercepTest in 158 cases, and FISH in 152 cases. The results</text>
<text top="214" left="315" width="240" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="5" tag_type="text">of these assays are summarized in Table 2 and their sensitivity<b>Hormone receptor, HER2, and p53 status</b></text>
<text top="226" left="315" width="100" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="5" tag_type="text">and specificity in Table 3.</text>
<text top="250" left="315" width="240" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="6" tag_type="text">The D07 antibody assay for p53 protein was informative in</text>
<text top="261" left="315" width="240" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="6" tag_type="text">150 cases; 57 tumors (38%) exhibited evidence of p53 pro-</text>
<text top="273" left="315" width="141" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="6" tag_type="text">tein over-expression by this method.</text>
<text top="297" left="315" width="62" height="8" font="font8" id="p1_t50" reading_order_no="47" segment_no="7" tag_type="title">p53 Mutations</text>
<text top="308" left="315" width="240" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="8" tag_type="text">Sequencing of exons 4 to 11 of the p53 gene was informative</text>
<text top="320" left="315" width="240" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="8" tag_type="text">in the 152 cases in which we were able to extract adequate<a href=""> 2 and th</a>eir sensitivity</text>
<text top="332" left="315" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="8" tag_type="text">DNA from the tumor specimen; 51 mutations were found in 44<a href="">e 3.</a></text>
<text top="344" left="315" width="240" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="8" tag_type="text">patients (29%). Tumors from six patients contained more than</text>
<text top="355" left="315" width="240" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="8" tag_type="text">one mutation in p53; in the remainder a single mutation was</text>
<text top="367" left="315" width="240" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="8" tag_type="text">identified. Approximately half were missense mutations, and</text>
<text top="379" left="315" width="240" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="8" tag_type="text">31% were categorized as 'other' (in intron sequences). The<b>p53 Mutations</b></text>
<text top="391" left="315" width="240" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="8" tag_type="text">remaining mutations were classified as splice mutations (9%)</text>
<text top="402" left="315" width="240" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="8" tag_type="text">or as silent, nonsense, or frameshift mutations (4% each). The</text>
<text top="414" left="315" width="240" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="8" tag_type="text">largest proportion of mutations was found in either intron 7</text>
<text top="426" left="315" width="240" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="8" tag_type="text">(27%) or exon 5 (22%). Mutations in exons 7 and exon 8</text>
<text top="438" left="315" width="240" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="8" tag_type="text">accounted for 12% and 18% of the identified mutations,</text>
<text top="449" left="315" width="240" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="8" tag_type="text">respectively. Mutations in exons 4 and 10 were rare, and there</text>
<text top="461" left="315" width="240" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="8" tag_type="text">were no mutations in exon 9. Only two tumors were found to</text>
<text top="485" left="56" width="28" height="7" font="font10" id="p1_t65" reading_order_no="62" segment_no="12" tag_type="title">Table 1</text>
<text top="503" left="56" width="85" height="7" font="font10" id="p1_t66" reading_order_no="63" segment_no="13" tag_type="text">Patient characteristics</text>
<text top="522" left="60" width="47" height="7" font="font1" id="p1_t67" reading_order_no="64" segment_no="14" tag_type="table">Characteristic</text>
<text top="522" left="274" width="79" height="7" font="font1" id="p1_t68" reading_order_no="65" segment_no="14" tag_type="table">Patients with biomarker</text>
<text top="530" left="274" width="50" height="7" font="font1" id="p1_t69" reading_order_no="66" segment_no="14" tag_type="table">measurements</text>
<text top="522" left="386" width="90" height="7" font="font1" id="p1_t70" reading_order_no="67" segment_no="14" tag_type="table">Patients without biomarker</text>
<text top="530" left="386" width="50" height="7" font="font1" id="p1_t71" reading_order_no="68" segment_no="14" tag_type="table">measurements</text>
<text top="522" left="512" width="25" height="7" font="font2" id="p1_t72" reading_order_no="69" segment_no="14" tag_type="table">P value<b>Table 1</b></text>
<text top="546" left="60" width="130" height="7" font="font1" id="p1_t73" reading_order_no="70" segment_no="14" tag_type="table">ER positive and/or PR positive ( n [%])<b>Patient characteristics</b></text>
<text top="546" left="274" width="33" height="7" font="font1" id="p1_t74" reading_order_no="71" segment_no="14" tag_type="table">85 (58%)</text>
<text top="546" left="386" width="38" height="7" font="font1" id="p1_t75" reading_order_no="72" segment_no="14" tag_type="table">159 (62%)</text>
<text top="546" left="512" width="19" height="7" font="font1" id="p1_t76" reading_order_no="73" segment_no="14" tag_type="table">0.45 a</text>
<text top="562" left="60" width="123" height="7" font="font1" id="p1_t77" reading_order_no="74" segment_no="14" tag_type="table">Prior adjuvant chemotherapy ( n [%])</text>
<text top="562" left="274" width="33" height="7" font="font1" id="p1_t78" reading_order_no="75" segment_no="14" tag_type="table">98 (60%)</text>
<text top="562" left="386" width="38" height="7" font="font1" id="p1_t79" reading_order_no="76" segment_no="14" tag_type="table">161 (56%)<i>P </i></text>
<text top="562" left="512" width="19" height="7" font="font1" id="p1_t80" reading_order_no="77" segment_no="14" tag_type="table">0.31 a</text>
<text top="577" left="60" width="161" height="7" font="font1" id="p1_t81" reading_order_no="78" segment_no="14" tag_type="table">Objective response (complete or partial; n [%])</text>
<text top="577" left="274" width="33" height="7" font="font1" id="p1_t82" reading_order_no="79" segment_no="14" tag_type="table">38 (24%)<i>n </i></text>
<text top="577" left="386" width="33" height="7" font="font1" id="p1_t83" reading_order_no="80" segment_no="14" tag_type="table">66 (23%)</text>
<text top="577" left="512" width="19" height="7" font="font1" id="p1_t84" reading_order_no="81" segment_no="14" tag_type="table">0.88 a</text>
<text top="593" left="60" width="65" height="7" font="font1" id="p1_t85" reading_order_no="82" segment_no="14" tag_type="table">Median age (years)</text>
<text top="593" left="274" width="16" height="7" font="font1" id="p1_t86" reading_order_no="83" segment_no="14" tag_type="table">54.9</text>
<text top="593" left="386" width="16" height="7" font="font1" id="p1_t87" reading_order_no="84" segment_no="14" tag_type="table">57.2</text>
<text top="593" left="512" width="19" height="7" font="font1" id="p1_t88" reading_order_no="85" segment_no="14" tag_type="table">0.25 b</text>
<text top="608" left="60" width="83" height="7" font="font1" id="p1_t89" reading_order_no="86" segment_no="14" tag_type="table">Median follow up (years)<i>n </i></text>
<text top="608" left="274" width="11" height="7" font="font1" id="p1_t90" reading_order_no="87" segment_no="14" tag_type="table">8.3</text>
<text top="608" left="386" width="11" height="7" font="font1" id="p1_t91" reading_order_no="88" segment_no="14" tag_type="table">8.5</text>
<text top="608" left="512" width="19" height="7" font="font1" id="p1_t92" reading_order_no="89" segment_no="14" tag_type="table">0.77 b</text>
<text top="624" left="60" width="128" height="7" font="font1" id="p1_t93" reading_order_no="90" segment_no="14" tag_type="table">Median number of metastatic sites ( n )</text>
<text top="624" left="274" width="5" height="7" font="font1" id="p1_t94" reading_order_no="91" segment_no="14" tag_type="table">1</text>
<text top="624" left="386" width="5" height="7" font="font1" id="p1_t95" reading_order_no="92" segment_no="14" tag_type="table">1</text>
<text top="624" left="512" width="19" height="7" font="font1" id="p1_t96" reading_order_no="93" segment_no="14" tag_type="table">0.14 b<i>n </i></text>
<text top="639" left="60" width="128" height="7" font="font1" id="p1_t97" reading_order_no="94" segment_no="14" tag_type="table">Median disease-free survival (months)</text>
<text top="639" left="274" width="9" height="7" font="font1" id="p1_t98" reading_order_no="95" segment_no="14" tag_type="table">19</text>
<text top="639" left="386" width="9" height="7" font="font1" id="p1_t99" reading_order_no="96" segment_no="14" tag_type="table">31</text>
<text top="639" left="512" width="29" height="7" font="font1" id="p1_t100" reading_order_no="97" segment_no="14" tag_type="table">0.0003 b</text>
<text top="655" left="60" width="125" height="7" font="font1" id="p1_t101" reading_order_no="98" segment_no="14" tag_type="table">Median time to progression (months)</text>
<text top="655" left="274" width="11" height="7" font="font1" id="p1_t102" reading_order_no="99" segment_no="14" tag_type="table">4.1</text>
<text top="655" left="386" width="11" height="7" font="font1" id="p1_t103" reading_order_no="100" segment_no="14" tag_type="table">4.3</text>
<text top="655" left="512" width="19" height="7" font="font1" id="p1_t104" reading_order_no="101" segment_no="14" tag_type="table">0.62 c</text>
<text top="670" left="60" width="108" height="7" font="font1" id="p1_t105" reading_order_no="102" segment_no="14" tag_type="table">Median overall survival (months)</text>
<text top="670" left="274" width="16" height="7" font="font1" id="p1_t106" reading_order_no="103" segment_no="14" tag_type="table">12.6</text>
<text top="670" left="386" width="16" height="7" font="font1" id="p1_t107" reading_order_no="104" segment_no="14" tag_type="table">12.3</text>
<text top="670" left="512" width="19" height="7" font="font1" id="p1_t108" reading_order_no="105" segment_no="14" tag_type="table">0.81 c</text>
<text top="687" left="60" width="486" height="7" font="font1" id="p1_t109" reading_order_no="106" segment_no="15" tag_type="text">Note that data regarding hormone receptor status and prior adjuvant chemotherapy were not available for all patients enrolled in CALGB 9342,</text>
<text top="694" left="60" width="492" height="8" font="font1" id="p1_t110" reading_order_no="107" segment_no="15" tag_type="text">and the total number is therefore less than 469 for some of the comparisons. a P value is based on the test for comparing two proportions. b P value</text>
<text top="702" left="60" width="491" height="8" font="font1" id="p1_t111" reading_order_no="108" segment_no="15" tag_type="text">is based on the Wilcoxon rank-sum test for comparing median values. c P value is based on a comparison of Kaplan-Meier curves with the log-rank</text>
<text top="711" left="60" width="14" height="7" font="font1" id="p1_t112" reading_order_no="109" segment_no="15" tag_type="text">test.</text>
</page>
</pdf2xml>
